UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2003
King Pharmaceuticals,Inc.
(Exact name of registrant as specified in its charter)
| Tennessee (State or other jurisdiction of incorporation) |
0—24425 (Commission File Number) |
54-1684963 (IRS Employer Identification Number) |
| 501 Fifth Street, Bristol, Tennessee (Address of principal executive offices) |
37620 (Zip Code) |
Registrant’s telephone number, including area code: 423-989-8000
Not Applicable
(Former name or former address, if changed since last report)
| SIGNATURE | ||||||||
| Exhibit Index | ||||||||
| EX-99.1 PRESS RELEASE | ||||||||
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(a) Financial Statements on Businesses Acquired.
| None. |
(b) Pro Forma Financial Information.
| None. |
(c) Exhibits.
| The following exhibits are filed pursuant to Item 601 of Regulation S-K: |
Exhibits:
| Exhibit | ||||||||
| Number | Description of Exhibit | |||||||
99.1 |
Press Release of King Pharmaceuticals, Inc. dated May 6, 2003. | |||||||
Item 9. Regulation FD Disclosure
On May 6, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, issued a press release which announced its first quarter 2003 financial results.
In accordance with the Securities and Exchange Commission (the “SEC”) Release No. 34-47583 and the General Instructions B.2. and B.6. of Form 8-K, the information contained in this report, which is intended to be furnished under Item 12, “Results of Operations and Financial Condition,” is instead being furnished under Item 9, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 6, 2003
| KING PHARMACEUTICALS, INC. |
| By: /s/ James R. Lattanzi James R. Lattanzi Chief Financial Officer |
Exhibit Index
| Exhibit | ||||||||
| Number | Description of Exhibit | |||||||
99.1 |
Press Release of King Pharmaceuticals, Inc. dated May 6, 2003. | |||||||